

**AMENDMENTS TO THE SPECIFICATION:**

**Please replace the 1<sup>st</sup> paragraph of page 1, as amended in the response filed on May 22, 2001, with the following rewritten paragraph:**

The application is ~~a continuation-in-part of International No. PCT/IB96/00461 filed May 15, 1996;~~ a continuation-in-part of U.S. Serial No. ~~[[08/877,571]]~~ 08/877,511, filed June 17, 1997, now U.S. Pat. No. 6,086,873, which is a continuation-in-part of International Application No. PCT/IB96/00461, filed May 15, 1996, now WO 97/42973 A1; ~~a continuation-in-part of U.S. Serial No. 09/094,598 filed June 15, 1998;~~ a continuation-in-part of U.S. Serial No. 08/913,290, a U.S. national stage application of International Application No. PCT/IB96/00461, filed under 35 U.S.C. § 371 on March 20, 1998, now U.S. Pat. No. 6,241,985; a continuation-in-part of U.S. Serial No. 09/152,698, filed September 2, 1998; and a continuation-in-part of PCT/IB99/01114, filed June 15, 1999, now WO 99/65517 A2. U.S. Serial No. 09/152,698 is also ~~a continuation-in-part of U.S. Serial Nos. 08/877,511 (now U.S. Pat. No. 6,086,873), 08/913,290 (now U.S. Pat. No. 6,241,985), and 09/094,598 (filed June 15, 1998, now abandoned, which is a continuation-in-part of both U.S. Serial No. 08/877,511 and International Application No. PCT/IB96/00461).~~ The teachings of each of these applications is are hereby incorporated by reference.

**Please replace the 1<sup>st</sup> full paragraph of page 28 with the following rewritten paragraph:**

In an embodiment of the invention, a suitable composition for the treatment of an ovarian tumor associated antigen contains a binding agent that binds the CA 125 antigen. Exemplary antibodies that bind to CA 125 include, but are not limited to B43.13. The mouse hybridoma B43.13 (MCB-ALT-96), which produces the antibody B43.13, was deposited with the American Type Culture Collection (ATCC), 10801 University Blvd., Manassas, VA 20110-2209, on May 18, 2000, and was given ATCC deposit number PTA-1883. The present invention also includes the use of any binding agent other than B43.13 that specifically binds to CA 125 and that results in a beneficial immune response, e.g., B27.1, or M11. These and other exemplary antibodies are

disclosed in Nustad, et al, Tumor Biology, 17:196-219 (1996) and Nap, et al, Tumor Biology, 17:325-331 (1996).

**Please replace the 2<sup>nd</sup> full paragraph of page 28 with the following rewritten paragraph:**

In another embodiment of the invention, a suitable composition for the treatment of gastrointestinal cancer contains a binding agent that binds the CA 19.9 antigen. Exemplary antibodies that bind to CA 19.9 include, but are not limited to Alt-3, W25 (CIS Bio International), A3 (Shemyakin Inst. Biorg. Chem.), and 1116-NS-19.9 ~~NS116-NS-19.9~~ (Centocor), among others. These and other exemplary antibodies are disclosed in Tumor Biology, 19:390-420 (1998). The mouse hybridoma AR44.6R1331, which produces the antibody Alt-3, was deposited with the American Type Culture Collection (ATCC), 10801 University Blvd., Manassas, VA 20110-2209, on November 17, 2000, and was given ATCC deposit number PTA-2691.

**Please replace the 4<sup>th</sup> full paragraph of page 28 with the following rewritten paragraph:**

In yet another embodiment of the invention, a suitable composition for the treatment of prostate cancer contains a binding agent that binds the prostate specific antigen (PSA). An exemplary antibody that binds to PSA includes, but is not limited to AR47.47. The mouse hybridoma AR47.47, which produces the antibody AR47.47, was deposited with the American Type Culture Collection (ATCC), 10801 University Blvd., Manassas, VA 20110-2209, on April 29, 1998, and was given ATCC deposit number HB-12526.

**Please replace the last paragraph of page 28 with the following rewritten paragraph:**

In yet another embodiment of the invention, a suitable composition for the treatment of inflammation includes a binding agent that binds CA 19.9 antigen. Exemplary antibodies that bind to CA 19.9 and reduce inflammation include but are not limited to Alt-3 and Alt-4 antibodies. The mouse hybridoma AR18.4R3313, which produces the antibody Alt-4, was deposited with the

Application No. 09/376,604  
Amendment dated February 8, 2007  
Reply to Office Action of August 9, 2006

Docket No.: AREX-P03-004

American Type Culture Collection (ATCC), 10801 University Blvd., Manassas, VA 20110-2209,  
on November 17, 2000, and was given ATCC deposit number PTA-2692.